argenx SE of the Netherlands has raised $1.27 billion from a global share offering after the exercise by underwriters of their options to buy more shares. This is an increase from the initial gross proceeds of $1.1 billion and will support development of the company’s pipeline of therapies for severe autoimmune diseases.
